AR and posterior cortical atrophy: In other words, the dual intervention of proxalutamide in the AR axis (e.g., AR expression and AR signal transcription [16]) and endogenous metabolism (e.g., lipogenesis and nucleotide synthesis [18]) will enable it to have a longer clinical service lifespan, from PCa to CRPC and drug-resistant CRPC.